StockIQ.techCoherus Oncology, Inc. (CHRS) Stock Analysis
Free AI-powered analysis and research for Coherus Oncology, Inc. stock
Sector: Healthcare
Full CHRS report
Coherus Oncology, Inc. (CHRS) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze CHRS Now →📰 Latest Update
Will Coherus Oncology (CHRS) Report Negative Earnings Next Week? What You Should Know
Mon, November 2, 2026 at 2:00 PM UTC 4 min read
Coherus Oncology (CHRS) is expected to report a quarterly loss of $0.22 per share, reflecting a year-over-year increase of 33.3%, with revenues projected at $15.9 million, up 37.4%. Analysts have a mixed outlook, as the Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.54%. The company has not beaten consensus EPS estimates in the last four quarters, making it challenging to predict a positive outcome for the upcoming earnings report on November 9.